In a nutshell This trial is aiming to examine the effectiveness of ipatasertib in combination with atezolizumab (Tecentriq) and paclitaxel (Taxol) for the treatment of advanced triple-negative breast cancer (TNBC) that cannot be surgically removed. The main outcomes to be measured in this trial is survival without progression of the disease and...
Read More
In a nutshell This phase 2 trial will investigate the safety of experimental treatment zanidatamab (ZW25) in combination with palbociclib (Ibrance) and fulvestrant (Faslodex) in patients with advanced breast cancer (BC). The main outcomes evaluated will be the rate of side effects and survival without cancer worsening. This trial is...
Read More
In a nutshell The study investigated whether chemotherapy after surgery with or without docetaxel (Taxotere) has different outcomes in patients with different body mass indexes (BMI; a measurement of body weight in relation to height) and early breast cancer (BC). The main finding was that patients responded differently to docetaxel based on...
Read More
In a nutshell This study aimed to compare the safety and effectiveness of palbociclib and endocrine therapy to capecitabine chemotherapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. This study concluded that palbociclib and endocrine therapy is more effective than...
Read MoreIn a nutshell This study aimed to investigate the combination of letrozole and taselisib as a neoadjuvant treatment (before surgery) in patients with hormone receptor-positive, HER2-negative, early stage breast cancer. This study concluded that this treatment...
Read MoreIn a nutshell This study aimed to investigate the effectiveness and safety of talazoparib as a neoadjuvant agent (treatment before surgery) in patients with BRCA mutation and operable breast cancer. This study concluded that this treatment was a safe and effective in these patients. Some...
Read More
In a nutshell This study aimed to investigate the impact of early side effects requiring ado-trastuzumab emtansine dose interruptions or reductions on outcomes for patients with HER2+ advanced metastatic breast cancer. This study concluded that these side effects do not impact the outcomes for these patients. Some background...
Read MoreIn a nutshell This phase 2 study will investigate the safety and effectiveness of olaparib (Lynparza) alone or in combination with durvalumab (Infinzi) in advanced triple negative breast cancer (TNBC). The main outcome will be progression-free survival (PFS). This study is recruiting in Durham, North Carolina, US. The details...
Read More
In a nutshell This study evaluated the effectiveness of durvalumab (Imfinzi) combined with chemotherapy for patients with triple-negative breast cancer (TNBC). This study found that more patients treated with durvalumab had a complete disappearance of all signs of cancer (complete response) compared to placebo. Some...
Read MoreIn a nutshell This study evaluated the side effects associated with intensity-modulated radiation therapy (IMRT) for advanced breast cancer. This study found that most side effects were mild and did not lower quality of life for patients. Some background Radiotherapy is often performed in breast cancer patients after surgery. Previous studies have...
Read More
In a nutshell This phase 3 trial will investigate the effectiveness of pembrolizumab (Keytruda) in combination with pre-surgery chemotherapy and after-surgery hormonal therapy in patients with high-risk early-stage breast cancer (BC). The main outcomes to be measured will be the response to treatment and survival. The details...
Read MoreIn a nutshell The trial aims to investigate a new way of delivering radiation therapy in women with early-stage breast cancer. This will involve low doses of radiation therapy being aimed at the part of the breast where the tumor is or was. The main outcomes that will be measured are side effects and recurrence rate. This trial is recruiting in Missouri,...
Read More
